Haleos Labs Limited

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 06 May 2026, providing investors with the latest insights into the company’s performance and outlook.

With a decisive surge to Rs 1540 on 29 Apr 2026, Haleos Labs Limited has marked a fresh 52-week high, reflecting robust momentum across multiple technical indicators and outperforming its sector peers.

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 13 April 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall quality assessments, signalling a cautious but positive outlook for investors.

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 8 April 2026. This change reflects a deterioration in technical indicators despite the company’s positive quarterly financial performance and long-term market-beating returns. Investors are advised to weigh the mixed signals from quality, valuation, financial trends, and technicals before making decisions.

Haleos Labs Limited has seen its investment rating upgraded from Sell to Hold as of 2 April 2026, reflecting a notable shift in technical indicators and valuation metrics. Despite some lingering concerns over long-term fundamentals, the company’s recent financial performance and market behaviour have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

At Rs 1,253.80, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Haleos Labs Limited locked at its upper circuit of 5% on 1 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 25 March 2026. This revision reflects a combination of deteriorating technical indicators, subdued financial trends, and valuation challenges despite some positive quarterly performance. The downgrade underscores growing caution among investors amid mixed signals across key assessment parameters.

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 4 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Haleos Labs Limited, a key player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 4 March 2026. This revision reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, signalling a cautious but more optimistic outlook for investors amid mixed fundamental signals.

Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 February 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 14 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Haleos Labs Limited (NSE: HALEOSLABS), a micro-cap pharmaceutical company with a market capitalisation of ₹379.42 crores, delivered its strongest quarterly performance in Q3 FY26 (October-December 2025), posting consolidated net profit of ₹6.62 crores—an 8.52% quarter-on-quarter increase and a robust 21.02% year-on-year growth. The Hyderabad-based company, which operates in the highly competitive pharmaceuticals and biotechnology sector, saw its stock trading at ₹1,255.00 as of February 12, 2026, down 1.27% on the day but reflecting a complex narrative of operational improvement amidst valuation concerns.

Haleos Labs Limited has seen its investment rating upgraded from Sell to Hold as of 2 February 2026, reflecting a notable improvement in its technical indicators and valuation metrics. Despite lingering concerns over long-term fundamentals, recent quarterly financial performance and a shift in market sentiment have contributed to a more balanced outlook for this pharmaceuticals and biotechnology company.

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 1 Feb 2026, closing at ₹1240.0, marking a maximum daily gain of 4.91%. This sharp rally was driven by robust buying interest despite subdued trading volumes and a regulatory freeze on further price movement, reflecting strong investor sentiment amid sector headwinds.

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.